Home / China-US economic relations

    Policies to address 'drug lag' essential

    (China Daily)

    Updated: 2015-09-23 10:33:09

    Policies to address 'drug lag' essential

    Wu Xiaobin, president of Pfizer Investment China

    To coincide with President Xi Jinping's first state visit to the US, China Daily asked senior executives with American companies for their opinions on China's business environment.

    Companies in China are facing the challenge of rising costs. Will this affect your plans in China or will you continue to invest in the country? Do you have any plans to relocate to the US or elsewhere in the region?

    China is one of the fastest-growing pharmaceutical markets in the world, and the ongoing health care reforms in China will continue to drive the expansion of its pharmaceutical market and industry. Pfizer has demonstrated its commitment to improving health in China by introducing innovative drugs, partnering with local industry, conducting educational health care programs, supporting community health initiatives and actively promoting health care development.

    Pfizer will continue to invest in the Chinese market and support the health care reform. We will continue to partner with stakeholders to build a vibrant life sciences sector that develops treatments and cures for China and the world, while achieving the government's broader goals to boost development, increase wealth and promote social equity.

    How has the depreciation of the yuan affected your company? Will this play a major role in your decision to continue to invest and expand in the country and region?

    At this point, we can't comment or speculate on any potential impact the yuan depreciation has had on our financial expectations for 2015. What we can comment on is our commitment to China and our ongoing support for its health care reform goals.

    The Chinese government believes in a stable investment environment and has rolled out policies to help international companies here by increasing transparency. What other measures would improve business efficiency and competitiveness?

    Nurturing the life sciences sector, with the biopharmaceutical industry at its heart, can strengthen economic growth. Investment in R&D infrastructure and basic science will encourage the development of biomedical innovation and enhance the reputation of the China's life sciences hubs. China's Made in China 2025 vision, for example, highlights the importance of the life science sector as a key driver of economic growth in the country.

    From a pharmaceutical industry perspective, we hope the Chinese government will further implement policies that support and encourage biopharmaceutical innovation, accelerate the approval process of new medicines, and enhance the quality of domestic generics to the international level. We're glad to see that the government has recently issued a series of new policies to address these.

    What are the greatest challenges your company faces in China, and how will you deal with them?

    The regulatory environment presents multiple challenges for companies trying to achieve simultaneous global development and registration of new medicines. In China, it can take up to eight years on average to register a treatment, compared with four in the US.

    Previous Page 1 2 Next Page

     
    ...
    视频一区二区中文字幕| 亚洲äv永久无码精品天堂久久| AV无码久久久久不卡蜜桃 | gogo少妇无码肉肉视频| 自拍中文精品无码| 亚洲中文字幕无码久久2020| 精品欧洲av无码一区二区三区| 人妻无码中文字幕免费视频蜜桃| 色吊丝中文字幕| 人妻少妇精品无码专区动漫| 无码伊人66久久大杳蕉网站谷歌| 中文字幕一区二区三区在线不卡| 无码人妻精品一区二| 国产午夜无码精品免费看| 久久久久亚洲AV无码专区首JN| 99久久无码一区人妻| 人妻丰满熟妇av无码区不卡| 亚洲色无码一区二区三区| 欧美日韩中文国产va另类| 中文字幕日本高清| 欧美日韩中文字幕久久伊人| 亚洲欧美日韩在线中文字幕| 中文字幕精品一区影音先锋| 亚洲国产精品无码中文字 | A最近中文在线| 特级小箩利无码毛片| 无码8090精品久久一区| 亚洲国产精品无码久久青草| 免费无码又爽又黄又刺激网站 | 熟妇人妻久久中文字幕| 亚洲中文字幕伊人久久无码| 亚洲男人在线无码视频| 中文字幕亚洲综合小综合在线| 亚洲av无码成人精品区| 色吊丝中文字幕| 激情欧美一区二区三区中文字幕| 中文字幕在线观看免费视频| 久久有码中文字幕| 国产成人亚洲综合无码| 亚洲AV无码久久精品蜜桃| 少妇人妻无码专区视频|